Molecular Formula | C15H14N2Na2O6S2 |
Molar Mass | 428.39 |
Melting Point | >173°C (dec.) |
Solubility | H2O: soluble50mg/mL |
Appearance | White solid |
Color | white to light yellow |
Merck | 13,9505 |
Storage Condition | 2-8°C |
Stability | Moisture sensitive |
Physical and Chemical Properties | Opalescent non-crystalline powder with hygroscopicity. Readily soluble in water (>100g/mL), the pH of the resulting clear solution is 6.0-8.0. Aqueous solution is relatively stable; Acidic solution is relatively unstable. |
In vitro study | Ticarcillin (64 mg/mL) for 90% of all β-lactamase-positive strains was reduced to 2 mg/mL on addition of clavulanic acid. Ticarcillin had a MICs of 4 mg/mL against 90% of all β-lactamase-negative strains. 93.4% of the β-lactamase producing strains were susceptible to Ticarcillin, with MICs less than or equal to 64 mg/ml. Ticarcillin/potassium clavulanate is photostable and resistant to inactivation by β-lactamase. Ticarcillin/potassium clavulanate is more economical than carbenicillin and cefotaxime in scavenging Agrobacterium tumefaciens at plant transformation. |
In vivo study | The mean elimination half-life of Ticarcillin (120 mg/kg) in serum was 70.8 minutes in control subjects and 53.1 minutes in patients with cystic fibrosis. Systemic clearance of Ticarcillin was significantly higher in cystic fibrosis patients (65.6 mL/min/m2 vs 46.2 mL/min/m2 control subjects). The non-renal clearance of Ticarcillin was also significantly higher in cystic fibrosis patients (24.8 mL/min/m2 vs 13.3 mL/min/m2 controls). The clinical success and failure rates of Ticarcillin/clavulanate (3.1g,iv, administered every 4-6 hours) for the treatment of complicated skin and skin structure infections were 80.3 and 19.7, respectively. In the microbiologically evaluable population, the overall eradication rate in the Ticarcillin/clavulanate treatment group was 83.7 percent. In the final evaluation of the treatment of pediatric and adult patients with abdominal infection, Ticarcillin/clavulanate had a cure rate of 79%. |
Risk Codes | R36/37/38 - Irritating to eyes, respiratory system and skin. R42 - May cause sensitization by inhalation R43 - May cause sensitization by skin contact R42/43 - May cause sensitization by inhalation and skin contact. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37 - Wear suitable protective clothing and gloves. |
WGK Germany | 2 |
RTECS | XM9410000 |